Outcomes based on age in the phase 3 Meteor trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)

被引：0
|
作者：
Bergmann, L. [1 ]
Donskov, F. [2 ]
Motzer, R. J. [3 ]
Voog, E. [4 ]
Hovey, E. J. [5 ]
Gruellich, C. [6 ]
Nott, L. M. [7 ]
Cuff, K. E. [8 ]
Gil, T. [9 ]
Jensen, N., V [10 ]
Chevreau, C. [11 ]
Negrier, S. [12 ]
Depenbusch, R. [13 ]
Cornelio, I [14 ]
Champsaur, A. [14 ]
Escudier, B. J. [15 ]
Pal, S. K. [16 ]
Powles, T. [17 ]
Choueiri, T. K. [18 ]
机构：
[1] Univ Klin Frankfurt Hosp, Frankfurt, Germany
[2] Aarhus Univ Hosp, Aarhus, Netherlands
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Ctr Jean Bernard Clin Victor Hugo, Le Mans, France
[5] Prince Wales Hosp, Sydney, NSW, Australia
[6] Natl Ctr Tumor Dis NCT Heidelberg, Heidelberg, Germany
[7] Royal Hobart Hosp, Hobart, Tas, Australia
[8] Princess Alexandra Hosp, Woolloongabba, Australia
[9] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[10] Odense Univ Hosp, Odense, Denmark
[11] IUCT Oncopole Inst Claudius Regaud, Toulouse, France
[12] Ctr Leon Berard, Ctr Reg Lutte Canc, Lyon, France
[13] Onkodok GmbH Dedicated Res Facil, Gutersloh, Germany
[14] Exelixis Inc, San Francisco, CA USA
[15] Gustave Roussy Canc Ctr, Villejuif, France
[16] City Hope Comprehens Canc Ctr, Duarte, CA USA
[17] Queen Mary Univ London, Barts Canc Inst, London, England
[18] Dana Farber Canc Ctr, Boston, MA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P600
引用
收藏
页码：200 / 201
页数：2
相关论文
共 50 条
  • [1] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth J.
    Griillich, Carsten
    Nott, Louise M.
    Cuff, Katharine Ellen
    Gil, Thierry
    Jensen, Niels Viggo
    Chevreau, Christine
    Negrier, Sylvie
    Depenbusch, Reinhard
    Bergmann, Lothar
    Cornelio, Izzy
    Champsaur, Anne
    Escudier, Bernard J.
    Pal, Sumanta K.
    Powles, Thomas
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).
    Donskov, Frede
    Motzer, Robert J.
    Voog, Eric
    Hovey, Elizabeth J.
    Grullich, Carsten
    Nott, Louise M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [3] Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).
    Tannir, Nizar M.
    Powles, Thomas
    Escudier, Bernard J.
    Donskov, Frede
    Grunwald, Viktor
    Sternberg, Cora N.
    Schmidinger, Manuela
    Schoffski, Patrick
    Szczylik, Cezary
    Peltola, Katriina Johanna
    Nosov, Dmitry
    Melichar, Bohuslav
    Clary, Douglas O.
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
    Schmidinger, M.
    Tannir, N. M.
    Powles, T.
    Escudier, B. J.
    Donskov, F.
    Gruenwald, V
    Sternberg, C. N.
    Schoffski, P.
    Szczylik, C.
    Peltola, K. J.
    Nosov, D.
    Melichar, B.
    Clary, D. O.
    Scheffold, C.
    Motzer, R. J.
    Choueiri, T. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 200 - 200
  • [5] Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial
    Powles, T. B.
    Escudier, B.
    de Souza, P.
    Chowdhury, S.
    Pook, D.
    Harmenberg, U.
    Basappa, N.
    Geynisman, D.
    Merchan, J.
    Redman, B. G.
    Ryan, C.
    Goodman, O.
    Ho, T.
    Singh, P.
    Lougheed, J.
    Patel, M.
    Knox, J. J.
    Motzer, R. J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve in patients (pts) with advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Powles, Thomas
    Escudier, Bernard J.
    Tannir, Nizar M.
    Mainwaring, Paul
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae-Lyun
    Heng, Daniel Yick Chin
    Schmidinger, Manuela
    Aftab, Dana T.
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Pal, Sumanta K.
    Hutson, Thomas E.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)
    Tannir, N.
    Powles, T.
    Motzer, R. J.
    Rolland, F.
    Gravis, G.
    Staehler, M.
    Rink, M.
    Retz, M.
    Csoszi, T.
    McCaffrey, J.
    De Giorgi, U.
    Caserta, C.
    Cheporov, S.
    Esteban Gonzalez, E.
    Duran, I.
    Larkin, J. G.
    Berg, W.
    Clary, D.
    Escudier, B.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Regional Differences in the Phase III Meteor Study of Cabozantinib (CABO) Versus Everolimus (EVE) in Advanced Renal Cell Carcinoma (RCC)
    Mainwaring, Paul
    Tannir, Nizar M.
    Powles, Thomas
    Motzer, Robert J.
    Rolland, Frederic
    Gravis, Gwanaelle
    Staehler, Michael
    Rink, Michael
    Retz, Margitta
    Csoszi, Tibor
    McCaffrey, John A.
    De Giorgi, Ugo
    Caserta, Claudia
    Cheporov, Sergey
    Gonzalez, Emilio Esteban
    Duran, Ignacio
    Larkin, James G.
    Berg, William
    Clary, Douglas O.
    Escudier, Bernard
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 129 - 130
  • [9] Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)
    Cella, D.
    Escudier, B.
    Tannir, N.
    Powles, T.
    Donskov, F.
    Peltola, K.
    Schmidinger, M.
    Heng, D.
    Mainwaring, P.
    Hammers, H.
    Lee, J-L.
    Rini, B. I.
    Roth, B.
    Baer, J.
    Mangeshkar, M.
    Scheffold, C.
    Hutson, T.
    Pal, S.
    Motzer, J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
    Powles, T.
    Motzer, R. J.
    George, D. J.
    Jonasch, E.
    Pal, S.
    Tannir, N. M.
    Signoretti, S.
    Mai, T. H.
    Scheffold, C.
    Wang, E.
    Aftab, D. T.
    Escudier, B.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2017, 28
12345